…Levetiracetam does not show superiority over standard agents for patients newly-diagnosed with epilepsy, according to the results of the KOMET trial. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
…A pilot phase IIa study (NCT00948259) has reported promising effects of tideglusib, a novel inhibitor of glycogen synthase-3 (GSK-3), in 30 patients with mild to moderate Alzheimer’s disease (Del Ser et al. J Alzheimers Dis 2013;33:205-215). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
…There has been little information on the natural history of radiologically isolated syndrome (RIS) since it was first described in 2009 (Okuda et al. Neurology 2009;72:800-805). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
…of multiple sclerosis – teriflunomide (already available in the U.S. as Aubagio), and BG-12. They will join fingolimod (Gilenya), the first of the oral MS drugs (following the withdrawal of cladribine). Fingolimod is indicated as a first-line (in the U.S.) or second-line (in Canada) treatment for relapsing forms of MS (RRMS). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you regist…
…A pilot phase IIa study (NCT00948259) has reported promising effects of tideglusib, a novel inhibitor of glycogen synthase-3 (GSK-3), in 30 patients with mild to moderate Alzheimer’s disease (Del Ser et al. J Alzheimers Dis 2012; epublished August 30, 2012). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…